{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+Mg+Oral+Tablet", "query": { "intervention": "Rivaroxaban 2.5 Mg Oral Tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+Mg+Oral+Tablet&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T21:52:10.426Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05009862", "title": "The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Rivaroxaban 2.5 Mg Oral Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Aspirin 81Mg Ec Tab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 60, "start_date": "2022-04-19", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05009862" }, { "nct_id": "NCT00571649", "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Rivaroxaban placebo", "type": "DRUG" }, { "name": "Enoxaparin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 8101, "start_date": "2007-12", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571649" }, { "nct_id": "NCT00440193", "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin followed by VKA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3449, "start_date": "2007-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2014-02-27", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Redlands", "state": "California" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440193" }, { "nct_id": "NCT04059679", "title": "Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease", "Peripheral Artery Disease" ], "interventions": [ { "name": "Rivaroxaban 2.5 Mg Oral Tablet", "type": "DRUG" }, { "name": "Aspirin 81 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LifeBridge Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-01-30", "completion_date": "2021-08", "has_results": false, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04059679" }, { "nct_id": "NCT05180773", "title": "Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peripartum Cardiomyopathy, Postpartum" ], "interventions": [ { "name": "Bromocriptine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Guideline Directed Medical Therapy for Heart Failure (GDMT)", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Second Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dennis M. McNamara, MD, MS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 250, "start_date": "2022-07-27", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180773" }, { "nct_id": "NCT06831474", "title": "Excretion of Rivaroxaban in Human Breast Milk", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Postpartum", "VTE Prophylaxis", "VTE (Venous Thromboembolism)", "Rivaroxaban", "Breastfeeding", "Breast Milk Collection" ], "interventions": [ { "name": "Rivaroxaban 10 MG Oral Tablet", "type": "DRUG" }, { "name": "Rivaroxaban 20 MG Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2025-07", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06831474" }, { "nct_id": "NCT04169269", "title": "Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Deep Vein Thrombosis", "Venous Thromboembolism" ], "interventions": [ { "name": "Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters", "type": "DRUG" }, { "name": "Rivaroxaban 10 milligram Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Florida Orthopaedic Institute", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2020-01-13", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04169269" }, { "nct_id": "NCT00439725", "title": "Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1197, "start_date": "2007-02", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439725" }, { "nct_id": "NCT02504216", "title": "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral Artery Disease" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Rivaroxaban-Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 6564, "start_date": "2015-08-18", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 105, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Avondale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02504216" }, { "nct_id": "NCT02289703", "title": "A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Rivaroxaban 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2015-01", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-10-01T21:52:10.426Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289703" } ] }